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Abstract

Maternal diet and nutritional status have a direct impact on pregnancy course and
outcome. Nutrition is critical to the development of the human embryo and fetus. Each
year in the United States, approximately 4000 pregnancies are affected by neural tube
defects (NTD). The most important finding in recent years has been the relationship
between maternal folic acid status and NTDs. Other studies have found an association
between zinc deficiency and an increased risk for having an NTD-affected pregnancy.
Furthermore, some of the latest research has linked maternal obesity with the
development of NTDs. The cumulative data from several studies have clearly indicated
enormous savings in direct medical costs associated with the prevention of NTDs.
Improving the nutritional status of women of childbearing age can help to prevent NTDs,
resulting in substantial savings.
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fall periods in the life cycle, pregnancy is one of the most critical. When a

woman becomes pregnant, all the experiences of her past join with those of the present to
lay the foundation of a new life whose potential, in tum, will influence the welfare of
generations to come. At no other time does the well being of one individual so directly
depend on the well being of another as it does during pregnancy (1). Between the
moment of conception and the moment of birth, innumerable events determine the course
and outcome of fetal development and, ultimately, the health of the newborn infant.
Many of these events are beyond a woman's control, but a woman's nutrition throughout
the teen and adult years, including pregnancy is within her control. Nutrition is critical to
maternal health, prenatal development, and the development of the child long after birth
(2). During pregnancy, malnutrition exerts its effects by acting on critical periods in the
development of the embryo and fetus. A woman's nutrient needs during pregnancy are
higher than at any other time in her adult life and are greater for certain nutrients than for
others (2). The role of specific nutrients and nutrition in general, to promote optimal
outcomes of pregnancy for both infants and mothers is under study (3). One area
currently being studied is the role the maternal diet plays in altering the risk for the
development of neural tube defects (4).
Each year in the United States, approximately 4000 pregnancies are affected by
neural tube defects. The term neural tube defect (NTD) applies to any malformation of
the embryonic brain and/or spinal cord. The embryonic neural tube is formed 20 to 28
days after fertilization, which is generally before the pregnancy is confirmed (5). The
various forms ofNTD are characterized by incomplete development of the central
nervous system and its closely related structures. They may range in severity from
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anencephaly, to incomplete formation of the spinal cord, cranial bones, vertebral arches,
meninges, and overlying skin (6). Anencephaly, the absence of the cerebral hemispheres,
is incompatible with life. The absent brain is sometimes replaced by malformed cystic
neural tissue, which may be exposed or covered with skin. Varying portions of the
brainstem and spinal cord may be missing or malformed. It usually results in death in
utero or during the first few days after birth (7). Another NTD is an encephalocele,
which is a protrusion of nervous tissue and meninges through a skull defect, associated
with incomplete closure of the cranial vault. Most encephaloceles can be removed
without leaving a major functional disability (7).
Spina bifida is a defective closure of the vertebral column. It is one of the most
serious NTD associated with prolonged life. Its severity varies from the occult type to a
completely open spine (rachischisis) with severe neurologic disability and death. In spina
bifida cystica, the protruding sac can contain meninges (meningocele), spinal cord
(myelocele), or both (myelomeningocele) (7). Spina bifida is most common in the
lumbar, low thoracic, or sacral region, and usually extends for 3 to 6 vertebral segments.
When the spinal cord or lumbosacral nerve roots are involved in the spina bifida, varying
degrees of paralysis occur below the involved level. The paralysis usually affects bladder
and rectal functions. The neurogenic bladder causes an incomplete bladder emptying and
a high incidence of urinary tract infection, which may, in tum, lead to renal disease (8).
Neural tube defects are the most common of severe birth defects. In 1992, more
than 4,600 babies with a primary diagnosis ofNTD were discharged from U.S. hospitals,
representing $141 million in hospital charges (9). One leading manifestation ofNTD,
spina bifida, costs as much as $200 million annually in direct medical costs. The lifetime

economic cost to society per person with spina bifida is about $258,000 (9).

Studies

have shown the B vitamin, folic acid, to reduce the occurrence of spina bifida and
anencephaly by at least 50% when consumed daily before conception and during early
pregnancy (5,9,10,11). Based on the 1995 manufacture's suggested retail prices for
multivitamin supplements with folate ($25 per person), the total annual cost of
supplementation for all pregnant women is approximately $162 million. Thus, the
enormous lifetime cost of NTD offsets the cost of supplements (9).
Folate plays a crucial role in the development of the central nervous system
during the early weeks of gestation. The neural tube forms from the l ih to 19th day after
conception and closes by the 20th to the 28th day (11). For fighting NTD, folic acid needs
to be available in adequate amounts dming the first part of pregnancy (12). Because at
least 50% of pregnancies are unplanned, the daily intake of adequate folic acid by all
women of childbearing age is important (13).
Folate has an essential role in the transport of single-carbon units needed for DNA
synthesis, cell division, and tissue growth. Folate also plays a role in DNA methyJation,
an important factor in genetic expression and maintenance of chromosome structure (10).
The major form of folate in serum is 5-methyl-tetrahydrofolate. This is an important
transport form of folate and is the principal methyl donor for methionine synthase, a B 12requiring enzyme. Methionine, an essential amino acid, loses its methyl group by
reactions involving S-adenosylmethionine. The resulting homocysteine can be
remethylated in the presence of adequate amounts of 5-methyl-tetrahydrofolate and
vitamin B 12 to regenerate methionine, thus conserving the supply of this essential
nutrient. Failure ofregeneration may result in the accumulation of potentially toxic
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homocysteine levels (5). During the period of neurulation, a time of rapid cell
proliferation and complex developmental processes, flaws in these folate-mediated onecarbon transfers could be detrimental to normal development and closure of the neural
tube (13).
Recent information may help to explain folic acid's role in the prevention of
NTDs. First, in recent studies, homocysteine has been found to be elevated, in both the
plasma and amniotic fluid, in women with NTD-affected pregnancies as compared with
control subjects (4,5,6). Second, it appears that a frank deficiency of folic acid is not
required in women to have an NTD-affected pregnancy (5,6). However, there does
appear to be a trend toward lower folic acid levels in women with NTD-affected
pregnancies as compared with control patients.· This information suggests that there may
be a defect or block in a metabolic step or steps involving homocysteine metabolism,
causing an elevated homocysteine level. Higher homocysteine levels could indicate
inadequate remethylation to form methionine (5,6). One explanation may be that, at the
critical period of neural tube formation, the genetic information is sensitive to the
metabolic consequences of a lower than normal folate status. Perhaps, high
homocysteine, low methionine, or some other signal results in the incomplete closure of
the tube (5). At this time, the exact mechanism by which folate affects NTD is not
understood, but the benefits of folate for women of childbearing age are clear
(1,2,3,4,5,6,9,10,11,12,13).
Data from several studies have shown that NTD risk can be significantly lowered
when women take a folic acid-containing multivitamin supplement daily during the
periconceptional period (1,2,3,4,5,6,9,10,11,12,13). A summary of four intervention
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studies and four observational studies of folic acid and neural tube defects can be found
in Appendix A and B, respectively (6). All of the four intervention studies indicated a
reduction in risk for NTD-affected pregnancy in folic acid supplemented women with a
prior NTD-affected pregnancy. The women in the intervention studies were given
supplements ranging from 0.36-5 mg of folic acid, taken from one month before
conception through the first trimester. The reduction in risk ranged from 60% to a
complete protective effect in the women supplemented with 5 mg of folic acid (6). Three
of the four observational studies showed a lowered risk ofNTDs for women who had not
had a prior NTD-affected pregnancy and who consumed 0.4-0.8 mg of folic acid daily
from multivitamin supplements (6). The study that reported the absence of a relationship
between the periconceptional use of vitamins and the occurrence ofNTD lacked specific
information on dietary intake as well as biochemical indicators of vitamin status. It is
possible that women included in the NTD group had risk factors that could not be
overcome by multivitamin supplementation (e.g. older age) and that women from less
economically advantaged backgrounds may not have been equally represented in this
study (5,6).
In general, studies have shown that the level of folic acid supplementation most
often associated with NTD prevention is 0.4-0.8 mg per day (4,5,6,9,10,11,12,13).
Butterworth (5) reviewed several studies that have shown women who consume adequate
folate from natural sources or from foods fortified with folic acid, have a reduced risk of
having a NTD-affected pregnancy. However, the risk reductions were not as great or as
consistent as that seen in folate-supplemented women. A 1997 survey of 2,001 women
aged 18-45 found that 66% of the women surveyed had heard about the importance of
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folic acid, but only 30% took a multivitamin containing folic acid (10). This indicates
that more effort is needed to educate women of childbearing age that folic acid may
lower the risk of having a baby with a neural tube abnormality (10).
In 1992, the Public Health Service recommended that all women of childbearing
age who are capable of becoming pregnant consume 0.4 mg of folic acid daily (10). In
August of 1991, the Center for Disease Control issued a separate guideline for women
who have had a prior pregnancy affected by NTDs and who are planning to start a new
pregnancy. Since the risk of a subsequent child having a NTD is high, the guideline
called for the consumption of a 4.0 mg daily dose of folic acid, from at least one month
before conception through the first three months of pregnancy (6). One of the most
rigorously conducted studies on folate supplementation was a randomized controlled trial
sponsored by the British Medical Research Council. The study showed that high-dose
folic acid supplements (4.0 mg per·day) used by women who had a prior NTD-affected
pregnancy reduced the risk of having a subsequent NTD-affected pregnancy by 70% (6).
. Several forms of folate are found naturally in food; the majority of these are
tetrahydro derivatives bearing multiple glutamic acid units in gamma peptide linkage.
This configuration requires cleavage by an enzyme known as conjugase to bring about
optimal bioavailability and intestinal absorption (5). Inhibitory compounds known as
conjugase inhibitors affect availability of folate from food. The conjugase inhibitors
prevent the digestion of folate, which is necessary for folate absorption (15). As much as
50 to 95% of food folate may be destroyed during household preparation, food
processing, and storage (14). The synthetic form of folate used in vitamin supplements
does not require the conjugase digestion to promote intestinal absorption (5).
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In March of 1996, the Food and Drug Administration issued regulations requiring
that folic acid be added to enriched cereal grain products, such as flours, cereals, com
meals, pasta, and rice, by January of 1998. Although improved dietary intake offolic acid
has been suggested as the optimal approach to increase folic acid intake, it is unlikely that
necessary population-wide dietary changes can be easily accomplished. Dietary folate is
absorbed only 50% as effectively as supplemental folic acid, so at least 0.8 mg of dietary
folate would be needed on a daily basis to obtain the suggested 0.4 mg daily intake (13).
The average consumption of dietary folate by women of childbearing age in the United
States has been estimated to be about 0.2 mg per day (13). Since the average
consumption among women in the United States represents a fourfold deficit in meeting·
the suggested amount, at this time supplemental folic acid appears necessary to provide
protection against NTDs (13).
Folic acid supplement pills"containing 0.4 mg of folic acid are readily available,
as are multivitamin preparations containing folic acid. The larger doses (4.0 mg) of folic
acid may require a prescription. Folic acid is a water soluble vitamin, so any excess
consumed is usually excreted in the urine. The effects of higher doses are not well
known, although they include complicating the diagnosis of vitamin B 12 deficiency in
certain people. Irreversible neurologic damage may occur ifB
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is not diagnosed and

treated. Therefore, women should be careful to keep their total daily folate consumption
at less than 1 mg per day, unless advised otherwise by their physician (6). It is important
to caution against unreasonably high expectations of folic acid. Supplementation is
expected to avert some, but not all, NTDs (6,9). Thus, it is apparent that there may be
other factors involved in the development ofNTDs.

8

It has been postulated that dietary zinc deficiency may be teratogenic, and may be
a contributing factor in the development ofNTDs (16). Zinc is known to play a critical
role as a cofactor for numerous enzyme functions, including protein synthesis, nucleic
acid metabolism, and gene expression (17). Studies have shown that in the presence of
high concentrations of folate, zinc and folate form a complex in the intestinal lumen.
This complex then inhibits zinc absorption (15). Furthermore, the hydrolysis of dietary
folates requires a zinc-dependent enzyme in order to be metabolized and absorbed. Folic
acid has been shown to impair zinc absorption when the dietary zinc intake is low, but
not when zinc intake is high (18).
The requirement for zinc increases during pregnancy. The total incremental zinc
need for pregnancy in humans is about 15 mg. However, women do not appear to
increase their zinc intakes during pregnancy. The Recommended Dietary Allowance
(RDA) for non-pregnant women is· 12 mg of zinc per day (14). The average daily intake
remains constant at near 10 mg. Endogenous fecal zinc losses have not been measured in
pregnant women, but urinary zinc losses increase during pregnancy. By late pregnancy,
the concentration of circulating zinc is about 15 to 35% lower in pregnant women than in
nonpregnant women (18). This decline occurs as early as the first gestational month,
which is when the final closure of the neural tube takes place.
If women do not increase their zinc intakes, adequate delivery of zinc to the
developing fetus must be achieved by adjustments in zinc utilization (18). Studies have
failed to show an improvement in zinc absorption in human pregnancy. Unfortunately, it
seems that a zinc-deficient diet does not effectively move zinc from maternal bones. This
storage pool appears somewhat unavailable so that dietary deficiency can quickly have an
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impact on the mineral balance of the maternal organism as well as the development of the
fetus (1). If a women's zinc intake is low, and she is consuming the recommended
amount of folate, the folate may be impairing zinc absorption, leading to a zinc
deficiency. It is also important to consider the effect of a zinc deficiency on the
metabolism and absorption of folate, which requires a zinc dependent enzyme. If in fact
a zinc deficiency causes NTDs, the zinc-folate nutrient interactions may help to explain
some of the NTD-affected pregnancies seen in women who consume adequate folate.
In experimental animals, maternal zinc deficiency has consistently produced
defects of the central nervous system (1,2,18,19,20,21,22). Zinc deficiency has been
specifically implicated in the development of anencephaly and spina bifida (18). Animal
studies have shown that even short periods of maternal zinc deficiency have deleterious
implications for the fetus (16,20). This transient deficiency may be totally undetectable
with respect to maternal health. The pregnant rat is unable to mobilize sufficient zinc
from her own tissues to supply the needs of normal fetal development during periods of
inadequate dietary zinc (22).
The relationship between zinc nutriture and human birth defects is less clear. Few
studies with humans have been conducted on the development of NTDs in infants of zinc
deficient mothers. Epidemiologic data seem to support a relationship between zinc
deficiency and central nervous system malformation in humans (22). There are reports of
women from Sweden, Turkey, and Ireland who gave birth to offspring with congenital
malformations. The mother's of these NTD-affected infants had significantly lower
plasma zinc concentrations at delivery than mothers who had had normal offspring
(15,20,21). A study by Hurd et al (21) found an association between zinc deficiency,
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spina bifida, and anencephaly from studying the international incidence of NTD-affected
pregnancies. The results showed that significant zinc deficiency has been found in
Egypt, Turkey, and Iran where high rates of central nervous system anomalies are seen
(22). Another study done by Hambridge et al (16) reported the pregnancy outcomes of
patients with acrodermatitis enteropathica, the most severe zinc deficiency state
recognized in man. The infants of these mothers were born with NTDs, in which zinc
deficiency may have been a contributing factor.
Although the potential value of zinc supplementation has been examined, the data
don't seem to be as sufficient as the data from studies on folate supplementation to
require preconceptional zinc supplementation in an effort to reduced NTDs. However,
since the zinc intake of women of childbearing age appears to be marginal, and because
of the zinc-folate interactions, it seems appropriate to include guidelines for optimizing
zinc intake in prenatal nutrition counseling (1).
Besides deficiencies in folate and zinc contributing to NTDs, recent reports have
shown that overnutrition, as evidenced by maternal obesity, may also cause congenital
defects, particularly of the central nervous system (23,24,25). An association linking
obesity to NTDs is of considerable public health importance because the prevalence of
overweight women is high and continues to increase in the United States, and because
NTDs are one of the most common and severe congenital malformations (23). Latest
estimates from the United States indicate a national average prevalence of obesity of 33%
in women, and rates close to 50% in certain ethnic and regional subgroups (25).
Furthermore, as many as 10% of women in the United States are obese
periconceptionally (24).
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Studies have shown a two-fold increase in the risk for NTD-affected pregnancies
among obese women compared with women who were of average weight prior to
pregnancy (23,24,25). The increased risk was seen in women whose prepregnancy body
mass index (BMI) exceeded 29 kg/m 2 compared with women of an average BMI. Obesity
in these reports was defined using the Institute of Medicine's definition of obesity as a
BMI greater than 29 kg/m 2 (23,24).

Werler et al (23), gathered data from a case-control surveillance program ofbirth
defects. The subjects filled out a questionnaire, which included detailed inquiries about
vitamin supplementation, dietary intake of more than 100 specific food items,
prepregnant weight, and maternal height. The results showed a positive association
between increasing prepregnant weight and NTD risk, regardless of folate intake. There
was a threefold increase in risk estimated for the heaviest women, independent of
whether folate intake was below or above the recommended level of 0.4 mg. In normalweight women, those consuming high levels of folate had a relative risk of NTDs in line
with findings concerning the protective effects of folic acid. However, in women _
weighing more than 70 kg, folate had no significant protective effect (23). The finding
that folate seems to lose it's protective effect in obese women is in line with another
clinical trial, where the protective effect of zinc supplementation in reducing low birth
weight infants was achieved only in nonobese women (25).
A population-based case-control study by Shaw et al (24) also showed an
increased risk in neural tube defect-affected pregnancies among obese women. Subjects
in this study were interviewed to collect information on each woman concerning medical,
reproductive, and family history, as well as aspects of her employment, hobbies, vitamin
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intake, and activities associated with various lifestyle factors. Potential maternal
covariates considered included age, race/ethnicity, education, gravidity, alcohol use,
diabetes, any use of a vitamin containing folic acid in the period 3 months before and
after conception, and dietary intake of folate, zinc, and fat (24). The increased risk was
not attributable to maternal nonuse of a vitamin containing folic acid, diabetes, use of diet
pills, lower dietary folate or zinc intake, or an NTD-pregnancy history. Adjustments for
maternal age, education, gravidity, use of vitamins, and use of alcohol did not change the
odds ratio.
Compared to women with a prepregnancy BMI of 19-27 kg/m2, women whose
BMI was 28 kg/m 2 or more were at an increased risk for having an NTD-affected
pregnancy, and women whose BMI was 38 kg/m 2 or more had the largest risk. In both
studies (23,24), the risk for anencephaly was similar between women with a BMI greater
than 29 kg/m 2 and women with a BMI of29 kg/m 2 or less. The risk for spina bifida and
other NTDs was substantially higher for those women with a BMI greater than 29 kg/m 2 .
Shaw et al (24) observed an increased NTD risk for shorter obese women.
The mechanism by which increased weight may affect NTD risk is not clear, but
these data suggest it may involve something other than folate and zinc intake. Women
who are overweight may have compromised nutrient intakes and therefore may be at an
increased risk for delivering an infant with a congenital anomaly. The association
between obesity and an increased risk ofNTD in the studies by Werler (23) and Shaw
(24) was not readily explained by any known social, dietary, or medical confounders and
appeared to be independent of folate and zinc intake, suggesting that it might arise from a
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specific pathophysiologic disturbance of obesity. The many metabolic and endocrine
changes associated with obesity provide numerous potential candidates (25).
Obesity affects metabolic factors that may, in tum, have a direct effect on neural
tube development. Many alterations in metabolism have been observed in the person
who is obese. These may be discussed in terms of the effects on the adipose cell in
particular and effects on metabolism in general (8). As the adipocyte enlarges, it adapts
metabolically, with progressive inhibition of lipogenesis and inhibition of pentose shunt
enzymes. As fat cells become larger, they also become insulin-resistant. Among other
consequences, they have a decreased number of receptor sites on their cell membranes
(8). A variety of biochemical abnormalities may be present in the obese. Some of these
abnormalities include an abnormal glucose tolerance test, increased fasting levels of
plasma glucose and plasma insulin, and increased insulin response to a glucose load and
other cues for insulin release. Other biochemical abnormalities in the obese include
hypertriglyceridemia, elevated fasting levels of free fatty acid, and elevated plasma
ketones (8). Perhaps the change? caused by obesity affect the delivery of nutrients
needed for closure of the neural tube during gestation. The efficiency of placental
nutrient transfer is a determinant of fetal well-being. Obesity may have a deleterious
effect on the utilization and transfer of nutrients by reducing the surface area of the villi,
promoting insufficient vascularization, or by changing the hydrostatic pressure in the
intervillous space. All of these changes could potentially limit the supply of nutrients
available to the fetus, inhibit normal growth, and consequently contribute to the
development of neural tube defects (1).
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Over the years, many hypotheses have evolved to explain why some people
become fat while others remain lean. A defect in thermo genesis has been proposed as a
factor in excessive weight gain. In people of normal weight, adaptive thermo genesis
usually occurs. In this process, there is an increase in metabolic rate stimulated by eating,
which serves the purpose of burning off excess energy in the form of heat (26). A defect
in the thermic effect of food may alter the process of digestion, absorption, and
metabolism of nutrients, making them less available for utilization in the growth of the
fetus. This may be one possible explanation as to why zinc and folate intakes seem to
lose their protective effects in obese people. In a study by Fernandez-Lopez et al (27) on
obese rats, obesity did not seem to have a significant effect on the ability to absorb and
retain the minerals studied, but obesity was thought to effect the ability to use the
substrates. If obesity affects the human body's ability to use nutrients, this could help to
explain why obese women are at an increased risk for having NTD-affected pregnancies,
since the nutrients would be unavailable for use by the embryo and fetus.
The relation between heavy prepregnant weight and NTD risk appears to be clear,
but the underlying mechanism is not (23,24,25). Therefore, nutrition, metabolism, and
obesity must be studied further to better explain their roles in the development of the
neural tube. It seems that prevention of excess weight gain in women of childbearing age
would be an effective intervention to decrease the risk of having an NTD-affected
pregnancy.
Human studies and studies on experimental animals have clearly shown that
maternal diet and the nutritional status of women have a direct impact on the pregnancy
course and outcome. Improving the overall nutrition status of women can help to reduce
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the incidence and prevalence of NTDs. Efforts should specifically be directed toward
increasing the awareness of the benefits of folic acid among women of childbearing age
and preventing excess weight gain in adolescents and young women. Although the
potential value of zinc supplementation has been examined in several populations, the
data are judged to be insufficient at the present time to mandate the institution of
preconceptional zinc supplementation practices. However, since the zinc intake of
women is marginal, and because zinc is needed for the absorption and metabolism of
folate, prenatal nutrition counseling might appropriately include guidelines for optimizing
zinc intake, which may help to prevent NTDs (1). Strategies to prevent NTDs through
achieving optimal nutritional status in women of childbearing age, are urgently needed
and deserve considerable funding, since the economic benefits in reducing the burden of
NTDs would be substantial.
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Appendix A
Intervention Studies of Folic Acid and
Neural Tube Defects
Study
Laurence, et
al, 1981
(1)

Design
Randomized
controlled trial in
Wales

Subjects
Pregnant women with prior
NTD-affected pregnancy
Supplemented mothers took
4 mg of folic acid daily.
Unsupplemented mothers
took a placebo.

Exposure
Supplemented women were given
4 mg of folic acid or placebo
daily at least 1 month before
conception through 1st trimester.

Results
2 NTD-pregnancies among 60
supplemented women.
4 NTD-pregnancies among 51
placebo-treated women.
Relative risk=0.40, not statistically
significant.

Comments
60% reduction
in risk.

UKMRC
study, 1991
(2)

Randomized
controlled
multicenter trial in
UK and Hungary

Women given 4 mg of folic acid
or placebo daily at least 1 month
before conception through the 1st
trimester.

6 NTD-pregnancies among 593
supplemented women.
21 NTD-pregnancies among 602
unsupplemented women.
Relative risk=0.28, p<0.05

72% reduction
in risk.

Smithells, et
al, 1983
(3)

N onrandomized
controlled
multicenter trial in
UK

Women given 0.36 mg offolic
acid +_multivitamins or reported
no use from 1 month before
conception through the 1st
trimester.

3 NTD-pregnancies among 454
supplemented women.
24 NTD-pregnancies among 519
unsupplemented women.
Relative risk=0.14, p<0.05

86% reduction
in risk.

Verge!, et al,
1990
(4)

Nonrandomized
con tro lied trial in
Cuba

Pregnant women with prior
NTD-affected pregnancy:
Supplemented mothers took
4 mg offolic acid daily.
Unsupplemented mothers
took a placebo.
Pregnant women with prior
NTD-affected pregnancy:
Supplemented mothers took
0.36 mg folic acid+
multivitamins daily.
Unsupplemented mothers
took nothing.
Pregnant women with prior
NTD-affected pregnancy:
Supplemented mothers took
5 mg folic acid daily.
Unsupplemented mothers
took nothing.

Women given 5 mg of folic acid
or reported no use from 1 month
before conception through the 1st
trimester.

0 NTD-pregnancies among 81
supplemented women.
4 NTD-pregnancies among 114
untreated women.
Indeterminant protective effects,
not statistically significant.

Complete
protective
effect.

Table comes from:
Recommendations for the Use ofFolic Acid to Reduce the Number of Cases of Spina Bifida and Other Neural Tube Defects. MMWR-Morbidity and Mortality
Weekly Report. 1992;41(RR-14):1-7.

Studies summarized above:
1. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double blind randomized controlled trial of folate treatment before conception to prevent
recurrence of neural-tube defects. Br Med J. 1981;282: 1509-11.
2. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338: 131-7.
3. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Walker S, Schorah CJ, Wild J. Further experience of vitamin
. supplementation for the prevention of neural tube defect recurrences. Lancet. 1983; 1:1027-31.
4. Verge! RG, Sanchez LR, Heredero Bl, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban
experience. Prenat Diagn. 1990;10:149-52.

Appendix B
Observational Studies of Folic Acid and
Neural Tube Defects
Exposure
Subjects
NTD case babies and normal Multivitamin supplement
containing 0-0.8 mg offolic acid
control babies.
at least 1 month before
Pregnant women without a
conception through the 1st
prior NTD-affected
trimester.
pregnancy.

Study
Mulinare, et
al, 1988
(1)

Design
Case/control in
metropolitan
Atlanta

Bower and
Stanley,
1989
(2)

Case/control in
Western Australia

Spina bifida case babies and
normal control babies.
Pregnant women without a
prior NTD-affected
pregnancy.

Dietary folate and multivitamin
supplement at least 1 month
before conception through the 1st
trimester.

Mills, et al,
1989
(3)

Case/control in
California and
Illinois

NTD case babies and normal
control babies.
Pregnant women without a
prior NTD-affected
pregnancy.

Multivitamin + folate supplement
containing up to 0.8 mg offolic
acid + diet at least 1 month before
conception through the 1st
trimester.

Milunsky, et
al, 1989
(4)

Prospective cohort
in New England

NTD case babies and normal
control babies.
Pregnant women without a
prior NTD-affected
pregnancy.

Multivitamin+ folate supplement
containing 0.1-1.0 mg offolic
acid + diet at least 1 month before
conception through the 1st
trimester.

Results
24 supplemented and 157
unsupplemented NTD casewomen.
405 supplemented and 1,075
unsupplemented controls.
Odds ratio=0.40, p<0.05
77 NTD cases; 154 control
mothers in study. The highest
folate quartile was compared with
the lowest. An increasing
protective effect was observed
from the lowest to the highest
quartile.
Odds ratio=0.25, p<0.05.
89 supplemented and 214
unsupplemented NTD casewomen.
90 supplemented and 196
unsupplemented women controls.
Odds ratio=0.91, not statistically
significant.
10 NTD-pregnancies among
10,713 women who took
multivitamin + folate.
49 NTD-pregnancies among
11,944 women who took
multivitamins without folate.
Relative risk=0.28, p<0.05.

Comments
60% reduction
in risk.

75% reduction
in risk.

No protective
effect.

72% reduction
in risk.

Table comes from:
Recommendations for the Use of Folic Acid to Reduce the Number of Cases of Spina Bifida and Other Neural Tube Defects. MMWR-Morbidity and Mortality
Weekly Report. 1992;41(RR-14):1-7.
Studies summarized above:
1. Mulinare J, Cordero JF, Erikson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA. 1988;260:3141-5.
2. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust.
1989;150:613-9.
3. Mills JL, Rhoads GG, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Walden ME, Deppo OR, Hoffman HJ. The absence of a relation between
the periconceptional use of vitamins and neural-tube defects. N Engl J Med. 1989;321:430-5.
4. • Milunsky A, Jick H, Jick SS, Bruell CI, Maclaughlin DS, Rothman KJ, Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the
prevalence of neural tube defects. JAMA. 1989;262:1634.

